ANIKA THERAPEUTICS INC (ANIK) Stock Price, Quote, News and Overview
NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD
ANIK Quote, Performance and Key Statistics
10.83
-0.29 (-2.61%)
The current stock price of ANIK is 10.83 USD. In the past month the price decreased by -2.61%. In the past year, price decreased by -57.24%.
ANIK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.19 | 329.95B | ||
| AMGN | AMGEN INC | 13.44 | 150.08B | ||
| GILD | GILEAD SCIENCES INC | 13.9 | 133.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.87B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.76 | 56.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.50B | ||
| ARGX | ARGENX SE - ADR | 97.4 | 34.20B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.5 | 27.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.52B | ||
| NTRA | NATERA INC | N/A | 22.96B | ||
| BIIB | BIOGEN INC | 8.02 | 18.60B | ||
| INSM | INSMED INC | N/A | 18.53B |
Related stock screener links
About ANIK
Company Profile
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Company Info
ANIKA THERAPEUTICS INC
32 Wiggins Ave
Bedford MASSACHUSETTS 01730 US
CEO: Cheryl R. Blanchard
Employees: 288
Phone: 17814579000
ANIKA THERAPEUTICS INC / ANIK FAQ
What is the stock price of ANIKA THERAPEUTICS INC today?
The current stock price of ANIK is 10.83 USD. The price decreased by -2.61% in the last trading session.
What is the ticker symbol for ANIKA THERAPEUTICS INC stock?
The exchange symbol of ANIKA THERAPEUTICS INC is ANIK and it is listed on the Nasdaq exchange.
On which exchange is ANIK stock listed?
ANIK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANIKA THERAPEUTICS INC stock?
9 analysts have analysed ANIK and the average price target is 21.76 USD. This implies a price increase of 100.92% is expected in the next year compared to the current price of 10.83. Check the ANIKA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANIKA THERAPEUTICS INC worth?
ANIKA THERAPEUTICS INC (ANIK) has a market capitalization of 155.30M USD. This makes ANIK a Micro Cap stock.
How many employees does ANIKA THERAPEUTICS INC have?
ANIKA THERAPEUTICS INC (ANIK) currently has 288 employees.
What are the support and resistance levels for ANIKA THERAPEUTICS INC (ANIK) stock?
ANIKA THERAPEUTICS INC (ANIK) has a resistance level at 11.66. Check the full technical report for a detailed analysis of ANIK support and resistance levels.
Is ANIKA THERAPEUTICS INC (ANIK) expected to grow?
The Revenue of ANIKA THERAPEUTICS INC (ANIK) is expected to decline by -26.79% in the next year. Check the estimates tab for more information on the ANIK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ANIKA THERAPEUTICS INC (ANIK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANIK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANIK, evaluating the profitability, health, valuation and growth aspects
- ANIKA THERAPEUTICS INC (ANIK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANIKA THERAPEUTICS INC (ANIK) Sales and EPS estimates to see what analysts future expectations are.
- ANIKA THERAPEUTICS INC (ANIK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANIKA THERAPEUTICS INC (ANIK) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANIKA THERAPEUTICS INC (ANIK) Stock Chart to make your own analysis
- ANIKA THERAPEUTICS INC (ANIK) Latest news and press-releases to stay up to date.
Does ANIKA THERAPEUTICS INC (ANIK) stock pay dividends?
ANIK does not pay a dividend.
When does ANIKA THERAPEUTICS INC (ANIK) report earnings?
ANIKA THERAPEUTICS INC (ANIK) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of ANIKA THERAPEUTICS INC (ANIK)?
ANIKA THERAPEUTICS INC (ANIK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
What is the Short Interest ratio of ANIKA THERAPEUTICS INC (ANIK) stock?
The outstanding short interest for ANIKA THERAPEUTICS INC (ANIK) is 3% of its float. Check the ownership tab for more information on the ANIK short interest.
ANIK Technical Analysis
ANIK Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ANIK. While ANIK has a great health rating, there are worries on its profitability.
ANIK Financial Highlights
Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.77% | ||
| ROE | -38.24% | ||
| Debt/Equity | 0 |
ANIK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ANIK. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 45.8% and a revenue growth -26.79% for ANIK